Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ligand Pharm (NQ: LGND ) 103.82 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Ligand Pharm < Previous 1 2 3 Next > Looking Into Ligand Pharmaceuticals's Recent Short Interest August 16, 2024 Via Benzinga Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review August 09, 2024 After Monday's panicked global sell-off, markets have calmed down. Via Investor's Business Daily LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 August 06, 2024 LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts August 06, 2024 Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. Via Investor's Business Daily Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts July 30, 2024 Via Benzinga What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals June 28, 2024 Via Benzinga Earnings Scheduled For February 27, 2024 February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. Via Benzinga Ligand Pharmaceuticals's Earnings: A Preview February 26, 2024 Via Benzinga Where Ligand Pharmaceuticals Stands With Analysts September 19, 2023 Via Benzinga 3 Magnificent Growth Stocks to Buy Hand Over Fist May 22, 2024 Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst. Via The Motley Fool Topics Economy Exposures Interest Rates 3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off May 20, 2024 With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. Via InvestorPlace LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Don't Overlook These Top Medical Stocks As Q1 Earnings Approach May 07, 2024 While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and... Via Talk Markets 7 Small-Cap Stocks for the Thinking Speculator April 08, 2024 While these small-cap stocks may be miles away from Wall Street’s spotlight, they’re compelling enough to deliver some big surprises. Via InvestorPlace Analyst Expectations for Ligand Pharmaceuticals's Future August 23, 2023 Via Benzinga Recap: Ligand Pharmaceuticals Q1 Earnings May 04, 2023 Via Benzinga Ligand Pharmaceuticals Earnings Preview February 21, 2023 Via Benzinga Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know December 23, 2022 Via Benzinga Why Is Ligand Pharmaceuticals Stock Trading Higher Today? February 27, 2024 Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024. Via Benzinga Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session February 27, 2024 Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. Via Benzinga Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday February 27, 2024 U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 27, 2024 Via Benzinga Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's November 28, 2023 Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent Via Benzinga Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary September 19, 2023 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio... Via Benzinga Why Are Novan Shares Nosediving Today? July 17, 2023 Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to Via Benzinga 3 Stocks That Smart Investors Should Be Flocking to Now May 30, 2023 Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. Via InvestorPlace Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial May 16, 2023 Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in Via Benzinga Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment February 21, 2023 Via Benzinga February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More January 31, 2023 The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... Via Benzinga Earnings Scheduled For February 22, 2023 February 22, 2023 Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.